Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Feb 20;9(4):1905-1912.
doi: 10.1002/ccr3.3900. eCollection 2021 Apr.

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6-NTRK3 gene fusion

Fabián Pitoia  1
Affiliations
Case Reports

Complete response to larotrectinib treatment in a patient with papillary thyroid cancer harboring an ETV6-NTRK3 gene fusion

Fabián Pitoia. Clin Case Rep. .

Abstract

Larotrectinib, a highly selective TRK inhibitor, was administered to a patient with rapidly progressing radioactive iodine-refractory papillary NTRK3 fusion-positive thyroid cancer. The patient achieved a durable (sustained for 11 months) complete response after 2 months of treatment and complete intracranial responses in metastatic brain lesions after 7 months of treatment. Larotrectinib may provide a therapeutic route for patients with RAI-R-differentiated thyroid cancer who might otherwise have few treatment options.

Keywords: iodine uptake and iodine metabolism; thyroid cancer‐clinical; thyroid cancer‐genetics.

PubMed Disclaimer

Conflict of interest statement

Fabián Pitoia discloses speaker bureau/expert testimony fees/honoraria from Bayer, Exelixis, Sanofi, Grupo Biotoscana (Representative of EISAI in Argentina), and Raffo Laboratory.

Figures

FIGURE 1
FIGURE 1
Treatment pathway of a patient with PTC who progressed on sorafenib and lenvatinib, and who achieved a complete response with larotrectinib treatment. AE, adverse event; PTC, papillary thyroid cancer; RAI, radioactive iodine
FIGURE 2
FIGURE 2
A diagnosis of RAI‐R thyroid cancer was based on the presence of multiple metastatic sites revealed with 18F‐FDG uptake in the first PET/CT scan conducted in April 2018. Diffuse lesions in soft and muscular tissues, multiple 18F‐FDG uptake in bones, and a large target lesion in the left lung were observed (arrow) (transverse view). 18 F‐FDG, 2‐deoxy‐2‐[fluorine‐18] fluoro‐D‐glucose; PET/CT, positron emission tomography/computed tomography; RAI‐R, radioiodine refractory
FIGURE 3
FIGURE 3
The extent of metastatic disease following treatment was determined by 18F‐FDG uptake in the PET/CT scan conducted in August 2019 after 6 months of sorafenib treatment (reduced to 600 mg/day) and 5 months of lenvatinib treatment (20 mg/day). Multiple lymph node metastases were observed in the neck and mediastinum, with multiple secondary lesions in subcutaneous tissues and muscles, the liver, adrenal gland, and right pleura were identified (coronal view). 18 F‐FDG, 2‐deoxy‐2‐[fluorine‐18] fluoro‐D‐glucose; PET/CT, positron emission tomography/computed tomography
FIGURE 4
FIGURE 4
After 4 weeks on larotrectinib treatment, an 18F‐FDG PET/CT scan showed a near‐complete response—only neck lymph node and lung (arrowed) lesions persisted in October 2019 after 4 weeks of larotrectinib (200 mg/day) treatment (transverse view); most lesions had disappeared. 18 F‐FDG, 2‐deoxy‐2‐[fluorine‐18] fluoro‐D‐glucose; PET/CT, positron emission tomography/computed tomography
FIGURE 5
FIGURE 5
Complete response after 8 weeks of larotrectinib (200 mg/day) treatment in November 2019. No lesions with 18F‐FDG uptake were observed during the PET/CT scan. 18 F‐FDG, 2‐deoxy‐2‐[fluorine‐18] fluoro‐D‐glucose; PET/CT, positron emission tomography/computed tomography
FIGURE 6
FIGURE 6
Intracranial response of metastatic lesions in the brain following larotrectinib (200 mg/day) treatment. MRI scans show substantial reductions in lesion sizes following 7 months of treatment. MRI, magnetic resonance imaging
See this image and copyright information in PMC

References

    1. Fugazzola L, Elisei R, Fuhrer D, et al. 2019 European Thyroid Association Guidelines for the treatment and follow‐up of advanced radioiodine‐refractory thyroid cancer. Eur Thyroid J. 2019;8:227‐245. - PMC - PubMed
    1. James BC, Mitchell JM, Jeon HD, Vasilottos N, Grogan RH, Aschebrook‐Kilfoy B. An update in international trends in incidence rates of thyroid cancer, 1973–2007. Cancer Causes Control. 2018;29:465‐473. - PubMed
    1. Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014;140:317‐322. - PubMed
    1. Kim J, Gosnell JE, Roman SA. Geographic influences in the global rise of thyroid cancer. Nat Rev Endocrinol. 2020;16:17‐29. - PubMed
    1. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1‐133. - PMC - PubMed

Publication types

LinkOut - more resources